Relmada Therapeutics said yesterday its therapy to treat major depressive disorder did not meet the main goal of a late-stage study.
The drug, REL-1017, did not show statistically significant improvement in symptoms of depression when compared to a placebo.
Relmada will continue to study REL-1017, its lead treatment, as an adjuntive or in combination with other depression drugs.
Major depressive disorder is a chronic condition that makes patients feel low, experience guilt and worthlessness. In extreme cases, it may lead to suicide.
Edits by EP News Bureau